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Abstract 
Background 
The purpose of this study was to analyze the detectability of colorectal neoplasia with 
fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography/computed 
tomography (FDG-PET/CT). 
Methods  
A total of 492 patients who had undergone both PET/CT and colonoscopy were analyzed. 
After determining findings of PET/CT and colonoscopy independently, the results were 
compared in each of the six colonic sites of all patients examined. The efficacy of PET/CT 
was determined using colonoscopic examination as a gold standard.  
Results  
In all, 270 colorectal lesions 5 mm or more in size, including 70 pathologically confirmed 
malignant lesions, were found in 172 patients with colonoscopy. The sensitivity and 
specificity of PET/CT for detecting any of the colorectal lesions were 36% and 98%, 
respectively. For detecting lesions 11 mm or larger, the sensitivity increased up to 85%, with 
the specificity remaining consistent (97%). Moreover, the sensitivity for tumors 21 mm or 
larger was 96% (48/50). Tumors with malignant or high-grade pathology were likely to be 
positive with PET/CT. Size of 10 mm or smaller (odds ratio, OR; 44.14, 95% confidence 
interval, CI; 11.44-221.67) and flat morphology (OR; 7.78, 95% CI; 1.79-36.25) were 
significant factors that were associated with false-negative cases in PET/CT. 
Conclusion 
Sensitivity of PET/CT for colorectal lesions is acceptable, showing size- and 
pathology-dependence, suggesting for the most part, that clinically relevant lesions are 
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detectable with PET/CT. However, it should be cautioned that there are cases with 
false-negative results, when considering PET/CT for screening purposes. 
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INTRODUCTION 
Fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) is 
well accepted in the imaging workup of various malignancies. Accordingly, PET has been 
shown to detect a wide variety of tumor foci including lymphoma, melanoma, lung cancer and 
colorectal cancer (CRC). PET is now widely used and has shown high sensitivity in the 
diagnosis, staging, therapeutic monitoring, and restaging of diverse cancers [1]. Furthermore, 
combined PET/computed tomography (CT) is superior to PET or CT for localizing 
metabolically active foci and in readily distinguishing physiological activity from 
pathological findings [2]. However, PET/CT is occasionally faulted for revealing intense 
metabolic activity at sites not considered to be related with the malignant process under study, 
as well as not discovering all clinically relevant neoplastic lesions [3]. 
As for detecting colorectal neoplasia, colonoscopy has been considered to be the most 
accurate method. However, colonoscopy is sometimes burdensome for patients because of the 
requirement of the preparation with laxative use, abdominal fullness due to air insufflation, 
and possible complication occurring such as perforation. Recently, CT colonography (CTC) 
has been shown to have sensitivity up to 65% for 5 mm or more lesions, and 90% for 10 mm 
or more lesions [4]. However, as with colonoscopy CTC also requires a laxative and air 
insufflation. Although guaiac or immunochemical fecal occult blood tests are commonly used 
for CRC screening worldwide, the sensitivity of such tests alone are not satisfactory even if 
performed repeatedly [5-7]. 
The usefulness of PET or PET/CT, which is non-invasive and requires no particular 
preparations, for incidental detection of premalignant colonic lesions has been previously 
reported [8-11]. In addition, several studies have recently reported the detectability of 
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colorectal neoplasia by PET or PET/CT. However, these studies had problems in evaluating 
precisely the ability of PET. Principally, a small scale and/or a biased cohort were used 
[10,12,13], and all patients did not undergo both PET and colonoscopy [11,14-17]. In addition, 
no large scale studies using PET/CT have been conducted on detecting colorectal lesions 
according to morphology, pathology, and location. Therefore, the previous studies could not 
show unambiguous results regarding the usefulness of PET/CT for detecting colorectal 
lesions. It remains to be determined whether PET/CT can be used as a screening modality for 
colorectal malignancy and clinically relevant colorectal lesions. 
In this study, therefore, we examined the ability of PET/CT to detect colorectal 
neoplasia in a large cohort using the findings of colonoscopy as a gold standard. All patients 
of this cohort underwent both PET/CT and colonoscopy within an interval of one year. Using 
this large cohort, moreover, we determined the sensitivity of PET/CT for colonic neoplasia 
according to tumor characteristics such as pathology, morphology, and location. In addition, 
we determined patient and tumor factors contributing to false-negative results with PET/CT, 
because such cases are problematic in using PET/CT as a screening modality. 
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PATIENTS AND METHODS 
Patients 
This was a retrospective study based on chart and image reviews of patients who 
underwent both PET/CT and colonoscopy within one year. A total of 7,014 patients who were 
treated at Okayama University Hospital underwent PET/CT at Okayama Diagnostic Imaging 
Center between April 2006 and January 2010. Of these, 587 patients underwent colonoscopy 
at Okayama University Hospital in the same year before or after PET/CT. The following 
patients were excluded from the study: 54 patients who had history of prior colon resection; 
32 patients with incomplete colonoscopy; and 9 patients with a serum glucose level of over 
150 mg/dl measured at 18F-FDG injection. Thus, 492 patients (306 men; 62%, 186 women; 
38%) with a median age of 66 years (range 10-88) were analyzed. 
Demographic data, medical history including primary cancer, and indication for 
PET/CT of the patients were obtained from medical charts. This study was approved by the 
Institutional Review Board of Okayama University Graduate School of Medicine, Dentistry 
and Pharmaceutical Sciences. 
PET/CT imaging protocol 
PET/CT was taken in the recommended standard condition with PET/CT Scanner 
Biograph LOS/Sensation 16 (Siemens, Munich, Germany) at Okayama Diagnostic Imaging 
Center. All patients fasted for at least 5 hours before the PET/CT studies. A serum glucose 
level measured at the time of 18F-FDG injection was confirmed to be less than 150 mg/dl in 
all patients. 18F-FDG (3.7 MBq/kg body weight) was administered intravenously into the arm 
and the patient was then seated on a chair to rest for 90 minutes to uptake, while drinking 350 
ml of mineral water for hydration. A whole body PET/CT scan from the upper end of the orbit 
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to the femoral region was performed 90 minutes after the 18F-FDG administration. The 
patients were in the supine position and their bilateral upper limbs were elevated. The scans 
consisted of seven to eight bed positions, with 2.4 minutes per position. Urinary tract 
activities were minimized in most patients by the placement of a Foley catheter before 
injection of 18F-FDG and by administering furosemide and intravascular fluids after injection 
of 18F-FDG. PET images were scatter corrected and reconstructed using an ordered-subset 
expectation maximization (OSEM) iterative reconstruction algorithm and with the use of a 
post-reconstruction Gaussian filter (3 mm full width half maximum). A technical parameter 
for a 16-detector row helical CT induced a section thickness of 3 mm and was obtained from 
the base of the skull through the proximal thighs at 140 kV and 12 to 40 milliampere seconds 
for attenuation collection and diagnosis. 
Interpretation 
All 18F-FDG PET/CT images were interpreted by two of the authors (T.H. and Y.O.) 
without the knowledge of the results of colonoscopy. The colon was divided into six segments 
on PET/CT images: cecum, ascending colon (including hepatic flexure), transverse colon, 
descending colon (including splenic flexure), sigmoid colon, and rectum. This partition was 
established to accurately localize the 18F-FDG hotspots, allowing an easier matching with the 
colonoscopic findings. 
Any focal glucose uptake in the colon significantly higher than background was 
considered abnormal. Physiologic 18F-FDG uptake due to fecal stasis, if present, was 
distinguished from uptake due to the presence of neoplastic lesions, the former usually being 
diffuse, and by analyzing the CT images.  
Colonoscopy 
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On the day of the colonoscopy, the patients received a colonic lavage using two liters of 
a polyethylene glycol-based electrolyte solution for bowel preparation in accordance with the 
recommended protocol of the manufacturer (Ajinomoto Pharma, Tokyo, Japan). All 
colonoscopy cases were performed by an experienced endoscopist by using a colonoscope 
with magnifying function and narrow band imaging (CF-H260AZI, PCF-Q240ZI, EVIS 
LUCERA, Olympus, Tokyo, Japan). All tumors found at colonoscopy were observed with 
magnification using dye-spraying and NBI mode. Tumors were then endoscopically 
diagnosed as malignant lesions (CRC, lymphoma, or metastatic cancer) or nonmalignant 
polyps (adenoma or hyperplastic) according to the definitions of Kudo et al. and Katagiri et al 
[18-20]. All tumors which were suspicious of malignancy with magnifying colonoscopy were 
pathologically examined by using specimens collected with biopsy, polypectomy, or surgical 
resection. CRC was defined as an invasive cancer with involvement of the submucosal layer 
of the colorectum, and intramucosal carcinoma was defined as a high-grade adenoma. All 
polyps that were regarded as non-malignant were not examined pathologically, because a 
considerable number of patients had more serious disease than colorectal polyps. 
Endoscopists were blinded to the results of PET/CT if PET/CT was performed prior to 
colonoscopy.  
Colonoscopic findings were determined from colonoscopy reports written by the 
endoscopists. In addition, all endoscopic images recorded in digital media were reviewed and 
confirmed by two of the authors (J.K. and S.H.), who were blinded to the results of PET/CT. 
The location of tumors was determined and recorded by dividing the colon into six segments, 
as was done with PET/CT. Size of the tumors was determined by measuring extirpated 
specimens when polypectomy or surgical resection was performed. If tumors were not 
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resected, the size was estimated with endoscopic images. Macroscopic appearance of 
colorectal lesions was defined as protruded (pedunculated or sessile) or flat. A flat-type 
colorectal tumor was endoscopically defined by a height of less than half of its diameter, or 
histologically defined by thickness of the lesion of less than twice that of the adjacent normal 
colonic mucosa, with or without depressive areas [21,22]. 
Comparison of findings between PET/CT and colonoscopy 
After determining findings of PET/CT and colonoscopy independently, the results were 
compared in each of the six colonic sites of all patients examined. Sensitivity, specificity, 
positive predictive value (PPV), negative predictive value (NPV), and accuracy of PET/CT 
for colonic lesions were determined relative to colonoscopic findings as a gold standard. 
Polyps smaller than 5 mm found at colonoscopy were not included in the analysis, because 
PET/CT was insensitive to lesions smaller than 5 mm in the large intestine. When two or 
more polyps were found in each colonic site with colonoscopy, polyps of the greatest 
dimension were compared against their counterparts detected by PET/CT. In analysis by 
location, the proximal colon was defined as the cecum, ascending colon, and transverse colon, 
while the distal colon included the descending colon, sigmoid colon and rectum. In case 
PET/CT was performed after polypectomy during colonoscopy, the resected polyps were not 
counted. 
Statistical analysis 
Sensitivity, specificity, PPV, NPV, and accuracy were determined based on the 
comparison between PET/CT and colonoscopy findings at six colonic sites of all 492 patients. 
Ninety-five percent confidence intervals (95% CI) were calculated for these estimates. 
Univariate analyses were performed with the chi-squared test or Fisher's exact test, and a 
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multivariate analysis was performed with the logistic regression model. A two-sided P value 
of less than 0.05 was accepted as significant. Statistical analysis was conducted using JMP 8 
software (SAS Institute, Cary, NC). 
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RESULTS   
Patients and colonoscopic findings 
Table 1 summarizes the demographics and colonoscopy results of the 492 patients. In 
all, 270 colorectal lesions of 5 mm or more in size, including 70 pathologically confirmed 
malignant lesions, were found in 172 patients by colonoscopy. Among 200 polyps which 
were considered nonmalignant, 164 (82%) were 10 mm or smaller, 30 (15%) were 11-20 mm, 
and 6 (3%) were 21 mm or larger. High-grade adenoma or adenoma with villous component 
were seen in 24 polyps among 79 pathologically examined polyps. Malignant lesions 
consisted of 57 CRCs, 10 lymphomas, 2 cancers of adjacent organs penetrating to the 
colorectal lumen, and 1 metastatic tumor. The average size of the malignant lesions was 31 
mm (range 6-80).  
Diagnostic ability of PET/CT for colorectal lesions 
Table 2 shows the sensitivity, specificity, PPV, NPV, and accuracy of PET/CT for 
colorectal lesions. Positive or negative for PET/CT was determined at six colonic sites in each 
patient, and compared with the findings of colonoscopy. Hence, the data were obtained based 
on 2,952 colonic sites of the 492 patients. The median interval between colonoscopy and 
PET/CT was 14 days (range 0-364). 
The results are shown according to tumor size (5 mm or more: n = 270; 11 mm or more: 
n = 97; and 21 mm or more: n = 50). The sensitivity and specificity for tumors 5 mm or more 
were 36%, and 98%, respectively. Hence, the sensitivity for tumors with 5-10 mm in size was 
only 9.2% (16/173). However, the sensitivity for tumors 11 mm or more increased up to 85% 
(82/97). Moreover, the sensitivity for tumors 21 mm or more was 96% (48/50), suggesting 
that the sensitivity of PET/CT for colorectal lesions is size-dependent, and that a large part of 
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clinically relevant polyps (larger than 10 mm) are detectable with PET/CT. The specificity 
was above 96% for any tumors greater than 5 mm, suggesting that few tumors would be 
found in the PET/CT negative regions. Endoscopic findings and PET/CT images of one 
true-positive case and one false-negative case are shown in Figure 1. 
Sensitivity of PET/CT for colorectal lesions stratified by pathology 
The sensitivity of the PET/CT stratified by pathology is shown in Table 3. The 
sensitivity to high-grade adenoma and adenoma with villous component was analyzed for 24 
pathologically confirmed cases. Although the sensitivity to benign lesions of 5-10 mm was 
less than 10%, the sensitivity for malignant lesions of similar size was 33%. For 11-20 mm 
lesions, increased sensitivities were seen in malignant lesions (94%), high-grade or villous 
(80%), and other polyps (50%), respectively. Although almost all lesions measuring 21 mm or 
more were detectable with PET/CT regardless of pathology, there were two lesions that were 
negative in PET/CT. One was a 25 mm flat-type polyp in the cecum, and the other was a 30 
mm invasive cancer in the rectum. In the latter case, continuous physiologic 18F-FDG uptake 
was observed from the descending colon to the rectum. 
Sensitivity of PET/CT for colorectal lesions according to location and macroscopic 
appearance 
Next, the sensitivity of PET/CT for colorectal tumors was determined according to 
tumor location and macroscopic appearance (Table 4). In general, PET/CT was less sensitive 
to tumors in the proximal colon. In particular, the difference in sensitivity between proximal 
and distal colon was greater in 11-20 mm tumors (53% vs. 81%, respectively). 
Macroscopically flat lesions were likely to be negative in PET/CT (the sensitivity to 11-20 
mm tumors was 44% in flat vs. 79% in protruded), although the number of flat lesions was 
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small compared to that of protruded lesions. These results suggest that the detectability of 
colorectal lesions by PET/CT is different according to tumor location and/or morphology. 
Identification of factors that contribute to being false-negative in PET/CT 
Differences in sensitivity have been shown of PET/CT for colorectal lesions according 
to tumor characteristics. In clinical practice, false-negatives in PET/CT studies of clinically 
relevant lesions would be problematic. Factors that contributed to false-negative results in 
PET/CT were determined in detecting clinically relevant lesions including malignant lesions, 
high-grade or villous adenomas, and polyps larger than 10 mm. The parameters used in the 
multivariate analysis were patient gender and age, and tumor size, location, and macroscopic 
appearance (Table 5). The results revealed that small size (10 mm or smaller) (odds ratio, OR: 
44.14; 95% CI: 11.44-221.67) and flat morphology (OR: 7.78; 95% CI: 1.79-36.25) were 
significant factors that contributed to false-negatives in PET/CT. Small and/or flat tumors are 
likely to escape from being detected by PET/CT. 
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DISCUSSION 
In this study, we demonstrated the sensitivity of PET/CT for detecting colorectal 
lesions in a large cohort, in which approximately 500 patients had undergone both PET/CT 
and colonoscopy. To the best of our knowledge, this is the largest cohort among studies that 
have examined the performance of PET/CT for colorectal lesions. Besides using this large 
cohort, we analyzed the sensitivity of PET/CT according to tumor characteristics such as 
tumor size, pathology, morphology, and location. In particular, in-depth analysis regarding 
colonic location was performed by calculating sensitivity for each colonic section. This 
showed that there was a difference in sensitivity of PET/CT between the proximal and distal 
colons. Another original and strong facet of this study was the identification of factors 
contributing to false-negative results in PET/CT. Although PET/CT may have the potential to 
be used as a screening modality for colorectal neoplasia, data accounting for the pros and cons 
of the problem are limited. Successful identification of false-negative factors by using this 
large cohort may clarify the issues on this topic. 
We demonstrated the sensitivity of PET/CT for colorectal lesions larger than 10 mm 
was approximately 85%, which was similar to the results shown in the previous studies 
[13,23]. Although the size and pathology-dependence (higher in high-grade and villous 
component, and malignancy) of the sensitivity had also been observed in the previous reports 
[9,12,13], our large scale study provided sufficient data for confirming  the efficacy of 
PET/CT for detecting clinically relevant colorectal lesions. In contrast to previous reports, we 
calculated the specificity, PPV, NPV, and accuracy by dividing the total colon into six 
segments. Because the prevalence of colorectal lesions is relatively low, specificity, NPV, and 
accuracy were likely to be higher, while PPV tended to be lower than the results of the 
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previous reports. In clinical settings however, the interpretation of PET/CT images is usually 
made by dividing the colon as performed in this study, and hence these values may reflect the 
true performance of PET/CT for colorectal lesions. 
Our results indicated that neoplasia in the proximal colon and flat lesions were likely to 
be false-negative with PET/CT. In particular, flat appearance was an independent factor that 
contributed to being false-negative in PET/CT. Friedland et al. also reported that PET was 
insensitive to flat lesions [12]. They reported the sensitivity for flat lesions was 23% in 
precancerous lesions larger than 10 mm, which was lower than our results (50%, 6/12), 
possibly because PET alone is less sensitive than PET/CT for colonic lesions [2]. In addition, 
the difference may be attributed to the fact that almost all (11/13) of the flat lesions they 
reported were located in the proximal colon, in which polyps are likely to be insensitive to 
PET. 
Although the precise reasons for the insensitivity of PET/CT to flat and/or proximal 
colonic neoplasia are unknown, the following factors may be involved. First, it may be 
affected by tumor volume. Because PET reflects metabolic activity of the tumor, sensitivity 
depends on tumor volume i.e., the number of tumor cells [24]. Flat lesions generally have 
smaller volumes and consist of smaller numbers of tumor cells than protruded lesions. 
Therefore, these lesions are insensitive to PET/CT. Second, because flat lesions are likely to 
be located in the proximal colon, tumor cells of proximal neoplasia may be different in 
glucose metabolism. Biological differences have been shown between proximal and distal 
colon cancers: proximal cancers are likely to be microsatellite unstable, hypermethylated, 
p53-wild, and diploid, while distal cancers tend to be chromosomal unstable, lower 
methylated, p53-mutated, and aneuploid [25-27]. Therefore, differences in glucose 
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metabolism may exist between proximal and distal neoplasia. A recent proteome analysis 
showed that glucose was lower in microsatellite instability high colorectal tumors than in 
microsatellite stable tumors [28]. In the future, we may be able to evaluate molecular 
differences in colorectal tumors according to positivity of PET/CT. Moreover, it has been 
reported that the growth rate of adenomas in the proximal colon is lower than that of 
adenomas in the distal colon [29]. Lower growth rate is probably correlated with lower rate of 
cell division, which involves poor glucose metabolism, resulting in poor sensitivity for 
PET/CT. 
We have shown that PET/CT has a reasonable sensitivity for clinically significant 
colorectal neoplasia. An emerging issue is the possibility of using PET/CT in screening for 
colorectal neoplasia. Minamimoto et al. reported that the sensitivity of PET and PET/CT for 
CRC in an asymptomatic population was 90%, on the basis of more than 50,000 cases 
analyzed in the Japanese Nationwide Survey [30]. Our results were comparable, though 
admittedly the data were of a lesser scale. The main goal of CRC screening is the detection of 
advanced neoplasia, and the sensitivity to those lesions was 75% in our study. The percentage 
is marginally lower than the sensitivity of CTC, which is a similar non-invasive 
radiology-based method. Previous studies indicated sensitivity of CTC for advanced 
colorectal neoplasia was 86-90%, and this method was recommended as one of the screening 
options for CRC by the American Gastroenterological Association [4,31,32]. PET/CT, 
however, has the advantages of not requiring bowel preparation and the detectability of 
cancers in other organs. These advantages may facilitate using PET/CT as a preferable 
screening test for cancers in the whole body including CRC. Although PET/CT is a 
non-invasive method, exposure to radiation, which may cause cancer development or affect 
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other health conditions, is a serious problem. Hence, PET/CT is impractical for annual or 
biannual screening purposes. Determining an optimal interval for CRC screening with 
PET/CT is a further problem, considering its questions of effectiveness and safety. 
In Japan, one session of whole-body PET/CT is provided at approximately $1000, 
which is higher than the cost of a colonoscopy, and much higher than the cost of a fecal occult 
blood test. Thus, PET/CT is a very expensive procedure only for the detection of colorectal 
neoplasia, regardless of its relatively high sensitivity and safety. At the same time, the cost of 
using PET/CT to detect malignancies in other organs as well as in the colorectum needs to be 
evaluated. Ultimately, PET/CT for screening use will be subjected to a cost effectiveness 
analysis. 
Our data concurred with previous studies in that colonoscopy should be performed in 
patients with positive results of PET/CT. However, for screening purposes, negative results of 
PET/CT do not justify dispensing with colonoscopies, regardless of false-negative patients. 
Our results, in particular, indicated that small but relevant lesions and flat lesions were likely 
to be missed by PET/CT. Although PET/CT could be used in whole body cancer screening, it 
should be noted that it is not perfect at least for CRC. Clinicians should inform patients in 
PET/CT screening of this limitation. For screening, PET/CT may be more practical when 
used in combination with a more non-invasive test such as a fecal occult blood test. 
It should also be noted that our results do not apply to inflammatory bowel disease 
(IBD)-related malignancy, because FDG can be incorporated in the intestine with 
inflammation. In fact, there have been reports regarding the feasibility of evaluating the 
inflammatory status of IBD with PET/CT [33]. In addition, a large part of dysplasia/cancer 
observed in ulcerative colitis are flat lesions, which are likely to escape detection with 
Hirakawa et al. 19 
PET/CT. The detection of IBD-related malignancies with PET/CT remains as an important 
problem, because no other modalities could definitively detect these lesions. 
The limitations of this study include those inherent in any retrospective analysis of a 
single institution's experience. Secondly, some of the locations detected by PET/CT may be 
inaccurate, because colonic location was determined with PET positivity by analyzing 
recorded CT images. However, coronal and sagittal section images of CT were used 
concurrently. Therefore, any inaccuracy of localization was considered minimal. Third, all 
polyps that were regarded as non-malignant were not examined pathologically, because a 
considerable number of patients had more serious disease than colorectal polyps. Therefore, 
‘other polyps’ in Table 3 may include some high-grade or villous adenomas, resulting in 
overestimation of the sensitivity to insignificant lesions. Fourth, since most of the patients in 
this study harbored a malignancy as an underlying disease, this precludes an accurate estimate 
of the utility of PET/CT as a screening tool for colorectal neoplasia in an asymptomatic 
population. In our study, 12% of the patients analyzed had colorectal malignancies, and 28% 
had colorectal polyps. The high prevalence of target lesions could make our data of 
sensitivities and specificities different from cases of an asymptomatic population. Fifth, we 
analyzed patients who had undergone both PET/CT and colonoscopy within a maximum 
interval of one year, which may be considered a wide range. However, since the actual 
median interval was 14 days, comparison of the results between the two methodologies was 
considered reasonable. Finally, although we used findings of colonoscopy as a gold standard, 
nevertheless, colonoscopy has been shown to be imperfect and can miss relevant polyps [34]. 
In conclusion, our study found that most of the clinically important colorectal lesions 
were detectable with PET/CT. However, it should be noted that smaller lesions, and flat 
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and/or proximal lesions are less sensitive to PET/CT. The interpretation of PET/CT study of a 
whole body should be performed, considering our findings in detection of colonic neoplasia. 
For use in CRC screening settings, there are still problems to be investigated including 
radiation exposure, appropriate screening intervals, and the existence of false-negative cases. 
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FIGURE LEGENDS 
Figure 1  
Endoscopic findings and PET/CT results of the representative cases: (a) Protruded polyp, 12 
mm in size, in the sigmoid colon with positive PET/CT results. (b) Flat lesion, 10 mm in size, 
in the cecum with false-negative PET/CT results. 
